{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T15:24:46Z","timestamp":1788449086125,"version":"build-2803163510"},"reference-count":40,"publisher":"Georg Thieme Verlag KG","issue":"08","license":[{"start":{"date-parts":[[2022,10,17]],"date-time":"2022-10-17T00:00:00Z","timestamp":1665964800000},"content-version":"vor","delay-in-days":77,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arq Neuropsiquiatr"],"published-print":{"date-parts":[[2022,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>\n          Background\u2003The Creutzfeldt-Jakob disease (CJD) is a spongiform encephalopathy that manifests as a rapidly progressive dementia syndrome. Currently, CJD has no cure, and many patients die within the first year, but some drugs are being studied as options for managing this condition.<\/jats:p><jats:p>\n          Objective\u2003To evaluate the effectiveness of pharmacological treatments offered to patients with CJD as a means to increase survival and reduce cognitive deterioration.<\/jats:p><jats:p>\n          Methods\u2003A systematic review of the literature was performed using 4 independent reviewers and 1 extra reviewer to resolve possible divergences in the search and analysis of papers indexed in MedLINE (PubMed), SciELO and Lilacs databases. The Medical Subject Heading (MeSH) terms used were: prion diseases, Creutzfeldt-Jakob disease, pharmacologic therapy, therapeutics, quinacrine, doxycycline, flupirtine, and pentosan polysulfate, with the Boolean operators AND and OR. This search included controlled clinical trials, uncontrolled clinical trials, and case series published from the year 2000 onwards, in the English language.<\/jats:p><jats:p>\n          Results\u2003A total of 85 papers were found using the descriptors used. At the end of the selection analyses, 9 articles remained, which were analyzed fully and individually.<\/jats:p><jats:p>\n          Conclusions\u2003None of the drugs evaluated proved significantly effective in increasing survival in patients with CJD. Flupirtine appears to have a beneficial effect in reducing cognitive deterioration in patients with CJD. However, additional studies are needed to establish better evidence and therapeutic options for the management of patients with CJD.<\/jats:p>","DOI":"10.1055\/s-0042-1755341","type":"journal-article","created":{"date-parts":[[2022,10,17]],"date-time":"2022-10-17T22:52:23Z","timestamp":1666047143000},"page":"837-844","source":"Crossref","is-referenced-by-count":17,"title":["Systematic review of pharmacological management in Creutzfeldt-Jakob disease: no options so far?"],"prefix":"10.1055","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0527-2753","authenticated-orcid":false,"given":"Luiz Henrique L\u00e9lis","family":"Miranda","sequence":"additional","affiliation":[{"name":"Universidade Federal de Pernambuco, Centro de Ci\u00eancias M\u00e9dicas, Departamento de Cl\u00ednica M\u00e9dica, Recife PE, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0655-6769","authenticated-orcid":false,"given":"Andr\u00e9 Felipe Pastick de Holanda","family":"Oliveira","sequence":"additional","affiliation":[{"name":"Universidade Federal de Pernambuco, Centro de Ci\u00eancias M\u00e9dicas, Departamento de Cl\u00ednica M\u00e9dica, Recife PE, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9275-4920","authenticated-orcid":false,"given":"Davi Mariano de","family":"Carvalho","sequence":"additional","affiliation":[{"name":"Universidade Federal de Pernambuco, Centro de Ci\u00eancias M\u00e9dicas, Departamento de Cl\u00ednica M\u00e9dica, Recife PE, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2777-2241","authenticated-orcid":false,"given":"Gustavo Marques Figueredo","family":"Souza","sequence":"additional","affiliation":[{"name":"Universidade Federal de Pernambuco, Centro de Ci\u00eancias M\u00e9dicas, Departamento de Cl\u00ednica M\u00e9dica, Recife PE, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7354-3039","authenticated-orcid":false,"given":"Jo\u00e3o Guilherme Monteiro","family":"Magalh\u00e3es","sequence":"additional","affiliation":[{"name":"Universidade Federal de Pernambuco, Centro de Ci\u00eancias M\u00e9dicas, Departamento de Cl\u00ednica M\u00e9dica, Recife PE, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3399-0023","authenticated-orcid":false,"given":"Joselmo Alberto Cabral","family":"J\u00fanior","sequence":"additional","affiliation":[{"name":"Universidade Federal de Pernambuco, Centro de Ci\u00eancias M\u00e9dicas, Departamento de Cl\u00ednica M\u00e9dica, Recife PE, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0819-0155","authenticated-orcid":false,"given":"Pedro Thadeu Mertens Brainer de Queiroz","family":"Lima","sequence":"additional","affiliation":[{"name":"Universidade Federal de Pernambuco, Centro de Ci\u00eancias M\u00e9dicas, Departamento de Cl\u00ednica M\u00e9dica, Recife PE, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8039-5417","authenticated-orcid":false,"given":"Renato Melo Aguiar","family":"J\u00fanior","sequence":"additional","affiliation":[{"name":"Universidade Federal de Pernambuco, Centro de Ci\u00eancias M\u00e9dicas, Departamento de Cl\u00ednica M\u00e9dica, Recife PE, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1751-6674","authenticated-orcid":false,"given":"S\u00e9rgio Pereira Lins","family":"Filho","sequence":"additional","affiliation":[{"name":"Universidade Federal de Pernambuco, Centro de Ci\u00eancias M\u00e9dicas, Departamento de Cl\u00ednica M\u00e9dica, Recife PE, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8072-337X","authenticated-orcid":false,"given":"Hugo Moura de Albuquerque","family":"Melo","sequence":"additional","affiliation":[{"name":"Universidade Federal de Pernambuco, Centro de Ci\u00eancias M\u00e9dicas, Departamento de Cl\u00ednica M\u00e9dica, Recife PE, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2022,10,17]]},"reference":[{"key":"ref1","first-page":"1612","article-title":"Prion Diseases","volume":"21","author":"M D Geschwind","year":"2015","journal-title":"Continuum (Minneap Minn)"},{"issue":"10","key":"ref2","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S1474-4422(05)70192-7","article-title":"Prion diseases","volume":"4","author":"R T Johnson","year":"2005","journal-title":"Lancet Neurol"},{"issue":"01","key":"ref3","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s40478-019-0742-2","article-title":"Sporadic Creutzfeldt-Jakob disease prion infection of human cerebral organoids","volume":"7","author":"B R Groveman","year":"2019","journal-title":"Acta Neuropathol Commun"},{"issue":"11","key":"ref4","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1080\/00207450903139762","article-title":"Sporadic Creutzfeldt-Jakob disease\u2013a review","volume":"119","author":"S Sharma","year":"2009","journal-title":"Int J Neurosci"},{"key":"ref5","volume-title":"Protocolo de notifica\u00e7\u00e3o e investiga\u00e7\u00e3o da doen\u00e7a de Creutzfeldt-Jakob com foco na identifica\u00e7\u00e3o da nova variante","author":"Minist\u00e9rio da Sa\u00fade","year":"2018"},{"issue":"01","key":"ref6","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1146\/annurev-pathmechdis-012418-013109","article-title":"Cellular and Molecular Mechanisms of Prion Disease","volume":"14","author":"C J Sigurdson","year":"2019","journal-title":"Annu Rev Pathol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"169","DOI":"10.3389\/fnmol.2019.00169","article-title":"Recent Advances in Understanding Mammalian Prion Structure: A Mini Review","volume":"12","author":"C Terry","year":"2019","journal-title":"Front Mol Neurosci"},{"issue":"02","key":"ref8","doi-asserted-by":"crossref","first-page":"e153","DOI":"10.1212\/WNL.0000000000008680","article-title":"Prion disease incidence in the United States: 2003-2015","volume":"94","author":"R A Maddox","year":"2020","journal-title":"Neurology"},{"issue":"01","key":"ref9","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1016\/S1473-3099(19)30615-2","article-title":"Creutzfeldt-Jakob disease: a systematic review of global incidence, prevalence, infectivity, and incubation","volume":"20","author":"L Uttley","year":"2020","journal-title":"Lancet Infect Dis"},{"issue":"05","key":"ref10","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1007\/s00415-017-8473-4","article-title":"Creutzfeldt-Jacob disease: new directions in diagnosis and therapeutics","volume":"264","author":"A Al-Ansari","year":"2017","journal-title":"J Neurol"},{"issue":"04","key":"ref11","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1001\/archneur.63.4.497","article-title":"Emerging pharmacotherapies for Creutzfeldt-Jakob disease","volume":"63","author":"C Korth","year":"2006","journal-title":"Arch Neurol"},{"issue":"01","key":"ref12","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1517\/21678707.2015.994605","article-title":"The future for treating Creutzfeldt\u2013Jakob disease","volume":"3","author":"V Vetrugno","year":"2015","journal-title":"Expert Opin Orphan Drugs"},{"key":"ref13","first-page":"399","volume-title":"Symptomatic treatment, care, and support of CJD patients","author":"B S Appleby","year":"2008"},{"issue":"02","key":"ref14","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.bsheal.2020.09.001","article-title":"Therapeutic implications of prion diseases","volume":"3","author":"C Chen","year":"2021","journal-title":"Biosafety Health"},{"issue":"05","key":"ref15","doi-asserted-by":"crossref","first-page":"E2","DOI":"10.3171\/2015.8.FOCUS15328","article-title":"Creutzfeldt-Jakob disease: updated diagnostic criteria, treatment algorithm, and the utility of brain biopsy","volume":"39","author":"M Manix","year":"2015","journal-title":"Neurosurg Focus"},{"issue":"04","key":"ref17","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/S1474-4422(09)70049-3","article-title":"Safety and efficacy of quinacrine in human prion disease (PRION-1 study): a patient-preference trial","volume":"8","author":"J Collinge","year":"2009","journal-title":"Lancet Neurol"},{"issue":"23","key":"ref18","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1212\/WNL.0b013e3182a9f3b4","article-title":"Quinacrine treatment trial for sporadic Creutzfeldt-Jakob disease","volume":"81","author":"M D Geschwind","year":"2013","journal-title":"Neurology"},{"issue":"12","key":"ref19","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1212\/01.WNL.0000148596.15681.4D","article-title":"Compassionate use of quinacrine in Creutzfeldt-Jakob disease fails to show significant effects","volume":"63","author":"S Ha\u00efk","year":"2004","journal-title":"Neurology"},{"issue":"03","key":"ref20","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1159\/000076350","article-title":"Results of quinacrine administration to patients with Creutzfeldt-Jakob disease","volume":"17","author":"M Nakajima","year":"2004","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"05","key":"ref21","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/j.1468-1331.2008.02108.x","article-title":"Intraventricular pentosan polysulphate in human prion diseases: an observational study in the UK","volume":"15","author":"I Bone","year":"2008","journal-title":"Eur J Neurol"},{"issue":"05","key":"ref22","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1111\/j.1440-1789.2009.01058.x","article-title":"Continuous intraventricular infusion of pentosan polysulfate: clinical trial against prion diseases","volume":"29","author":"Y Tsuboi","year":"2009","journal-title":"Neuropathology"},{"issue":"02","key":"ref23","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/S1474-4422(13)70307-7","article-title":"Doxycycline in Creutzfeldt-Jakob disease: a phase 2, randomised, double-blind, placebo-controlled trial","volume":"13","author":"S Ha\u00efk","year":"2014","journal-title":"Lancet Neurol"},{"issue":"02","key":"ref24","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1136\/jnnp-2016-313541","article-title":"Doxycycline in early CJD: a double-blinded randomised phase II and observational study","volume":"88","author":"D Varges","year":"2017","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"05","key":"ref25","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1212\/01.WNL.0000113764.35026.EF","article-title":"Efficacy of flupirtine on cognitive function in patients with CJD: A double-blind study","volume":"62","author":"M Otto","year":"2004","journal-title":"Neurology"},{"issue":"17","key":"ref26","doi-asserted-by":"crossref","first-page":"9836","DOI":"10.1073\/pnas.161274798","article-title":"Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease","volume":"98","author":"C Korth","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"ref27","doi-asserted-by":"crossref","first-page":"4894","DOI":"10.1128\/jvi.74.10.4894-4897.2000","article-title":"Lysosomotropic agents and cysteine protease inhibitors inhibit scrapie-associated prion protein accumulation","volume":"74","author":"K Doh-Ura","year":"2000","journal-title":"J Virol"},{"issue":"03","key":"ref29","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1101\/cshperspect.a024430","article-title":"Insights from Therapeutic Studies for PrP Prion Disease","volume":"7","author":"K Teruya","year":"2017","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"17","key":"ref30","doi-asserted-by":"crossref","first-page":"3563","DOI":"10.1021\/jm034093h","article-title":"Antimalarial drug quinacrine binds to C-terminal helix of cellular prion protein","volume":"46","author":"M Vogtherr","year":"2003","journal-title":"J Med Chem"},{"issue":"15","key":"ref31","doi-asserted-by":"crossref","first-page":"8462","DOI":"10.1128\/JVI.77.15.8462-8469.2003","article-title":"Evaluation of quinacrine treatment for prion diseases","volume":"77","author":"A Barret","year":"2003","journal-title":"J Virol"},{"issue":"04","key":"ref32","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/ana.10143","article-title":"Flupirtine blocks apoptosis in batten patient lymphoblasts and in human postmitotic CLN3- and CLN2-deficient neurons","volume":"51","author":"S Dhar","year":"2002","journal-title":"Ann Neurol"},{"issue":"06","key":"ref33","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1046\/j.1471-4159.1997.68062371.x","article-title":"Protection of flupirtine on beta-amyloid-induced apoptosis in neuronal cells in vitro: prevention of amyloid-induced glutathione depletion","volume":"68","author":"W E M\u00fcller","year":"1997","journal-title":"J Neurochem"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1007\/s007020050206","article-title":"Flupirtine shows functional NMDA receptor antagonism by enhancing Mg2+ block via activation of voltage independent potassium channels. Rapid communication","volume":"106","author":"J Kornhuber","year":"1999","journal-title":"J Neural Transm (Vienna)"},{"issue":"02","key":"ref35","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1006\/exnr.1997.6559","article-title":"Effect of flupirtine on Bcl-2 and glutathione level in neuronal cells treated in vitro with the prion protein fragment (PrP106-126)","volume":"147","author":"S Perovic","year":"1997","journal-title":"Exp Neurol"},{"issue":"05","key":"ref36","first-page":"1309","article-title":"Tetracycline affects abnormal properties of synthetic PrP peptides and PrPSc in vitro11Edited by J. Karn. Journal of Molecular Biology","volume":"300","author":"F Tagliavini","year":"2000"},{"issue":"01","key":"ref37","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2174\/1871526510909010023","article-title":"Tetracyclines and prion infectivity","volume":"9","author":"G Forloni","year":"2009","journal-title":"Infect Disord Drug Targets"},{"issue":"03","key":"ref38","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.3233\/JAD-170770","article-title":"Translational Research in Alzheimer's and Prion Diseases","volume":"62","author":"G Di Fede","year":"2018","journal-title":"J Alzheimers Dis"},{"issue":"09","key":"ref39","doi-asserted-by":"publisher","first-page":"e2010213118","DOI":"10.1073\/pnas.2010213118","article-title":"Unfolded and intermediate states of PrP play a key role in the mechanism of action of an antiprion chaperone","volume":"118","author":"R Petrosyan","year":"2021","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"02","key":"ref40","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1128\/jvi.67.2.643-650.1993","article-title":"Sulfated polyanion inhibition of scrapie-associated PrP accumulation in cultured cells","volume":"67","author":"B Caughey","year":"1993","journal-title":"J Virol"},{"issue":"10","key":"ref41","doi-asserted-by":"crossref","first-page":"4999","DOI":"10.1128\/JVI.78.10.4999-5006.2004","article-title":"Treatment of transmissible spongiform encephalopathy by intraventricular drug infusion in animal models","volume":"78","author":"K Doh-ura","year":"2004","journal-title":"J Virol"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"M J Page","year":"2021","journal-title":"BMJ"}],"container-title":["Arquivos de Neuro-Psiquiatria"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0042-1755341.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T23:56:14Z","timestamp":1682553374000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0042-1755341"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":40,"journal-issue":{"issue":"08","published-online":{"date-parts":[[2022,10,17]]},"published-print":{"date-parts":[[2022,8]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0042-1755341","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0004-282X","1678-4227"],"issn-type":[{"value":"0004-282X","type":"print"},{"value":"1678-4227","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8]]}}}